Safety and Efficacy Study of the NRT CQSS2 System for Smoking Cessation in Treatment-Seeking Subjects

NCT03178422 | Completed Phase 2 FDA Drug

• 1 other identifier: EF2016-003
• Study Type: interventional
• Target: 220
• Locations: 1 country
• Sites: 5

Brief Summary

Transdermal nicotine delivery systems are a cigarette smoking cessation aid designed to deliver nicotine into the systemic circulation via the skin. They have been found to reduce craving, thereby enhancing a patient's success for quitting smoking. However, side effects such as sleep disturbances and skin irritation, as well as incomplete smoking cessation are commonly experienced by users of such systems. Chrono Therapeutics, Inc. has developed an innovative programmable transdermal drug delivery system called the Chrono Quit Smoking Solution (CQSS2) that provides "off" periods (periods in which little to no nicotine is delivered), which is an advantage over existing systems that currently provide continuous delivery. The most important features of the CQSS2 are the periodic automatic dosing, plus the reduced side effects of sleep disturbances and potentially, skin irritation. The period when less nicotine is being delivered through the skin allows the skin an opportunity to "recover", thereby potentially reducing skin irritation. Another major benefit is the automatic dosing, which provides higher drug dosage at specific times of the day, leading to potentially greater success in quitting smoking. In this study, the CQSS2 will be used in conjunction with the Digital Coach application (app). The Digital Coach is a custom mobile app that provides behavioral support for the CQSS2. Together, the CQSS2 and the Digital Coach comprise the CQSS2 System.

Conditions

Smoking Cessation

Keywords

tobacco use cessation; smoking prevention; NRT

Outcome Measures

Primary Outcomes (1)

• Quit Rates for Smokers treated with the CQSS2 System vs NicoDerm CQ Patch

  Quit rates will be assessed by subject self-reporting, confirmed by Smokerlyzer testing, and documented by the Tobacco Outcome Measures Assessment. The Smoking Self Efficacy Questionnaire (SEQ12) will measure the subject's perceived ability to quit smoking.

  continuous abstinence from smoking during the last 4 weeks of treatment [Visit 3 through the end of study treatment]) in smokers (more than 10 cigarettes/day)

Secondary Outcomes (1)

• Number of participants with treatment-related adverse events as assessed on an 8-point Skin Irritation Assessment scale (0 to 7)

  From the time of the study drug application (6 week study period) until the last Follow-up visit.

Study Arms (2)

CQSS2 System (nicotine 21 mg)

EXPERIMENTAL

Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.

Drug: CQSS2

NicoDerm® CQ® patch (21 mg)

ACTIVE COMPARATOR

NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.

Drug: NicoDerm CQ Patch

Interventions

CQSS2 DRUG

Nicotine Replacement Therapy

Also known as: Chrono Quit Smoking Solution

CQSS2 System (nicotine 21 mg)

NicoDerm CQ Patch DRUG

Nicotine Replacement Therapy

Also known as: Nicotine patch

NicoDerm® CQ® patch (21 mg)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to participate fully in all aspects of the study.
• Ability to understand and sign the study informed consent form.
• English-speaking, literate males and females.
• Age ≥18 years.
• Smokers consuming on average \>10 cigarettes per day for the past 6 months, confirmed by self report.
• Carbon monoxide (CO) level ≥10 ppm, as determined by a Smokerlyzer breath test.
• Subject is in good health as determined by the Investigator.
• Subject has no known issues with completing all study visits.
• Subject must have regular access to Verizon Wireless at home as verified by www.opensignal.com or www.sensorly.com, at home wifi, or known connectivity to Verizon Wireless.

You may not qualify if:

• Subjects with screening clinical laboratory tests (complete blood count \[CBC\] with differential and platelets, and chemistry profile) outside the normal range and considered to be clinically significant by the Investigator.
• Subjects with severe hepatic, renal, cardiovascular, endocrine, or hematologic diseases who demonstrate abnormal electrolyte, hematology, and/or liver function (albumin, total protein, bilirubin) results on the screening blood laboratory tests, or with a history or illness that may (in the opinion of the Investigator) confound the results of the study or pose additional risk. Because these disorders may occur either alone or in combination, this judgment is left to the discretion of the Investigator caring for the subject.
• Subjects who are immunocompromised; have an infection or suspected infection with tuberculosis (TB) or hepatitis C virus (HCV); or have a suspected infection with, or history of, human immunodeficiency virus (HIV) or hepatitis B virus (HBV).
• Subjects with positive screening urine test for drugs of abuse, including opiates, amphetamines, barbiturates, methadone, oxycodone, benzodiazepines, cocaine, phencyclidine, methamphetamine, ecstasy, or cannabinoids; or with a history of use of cocaine, heroin, recreational drugs (e.g., MDMA/"ecstasy"), methamphetamine, or hallucinogens at any time during the past 3 months; or use of marijuana on a weekly basis for the past 3 months.
• Subjects with recent history (past 3 months) of abuse of, or dependence on, a substance other than tobacco, including: heavy alcohol consumption (i.e., if male, drinking \>4 alcoholic beverages per day for the past month and, if female, drinking \>3 alcoholic beverages per day for the past month).
• Subjects with physical examination (PE) abnormal findings considered to be clinically significant by the Investigator.
• Subjects with tattoos that could interfere with skin assessments.
• Subjects with any sign of infection, dermatologic disease, or condition that would inhibit transdermal absorption or might interfere with the evaluation of a test site reaction in locations where the investigational product may be used; or infection or condition (e.g., respiratory infection, strep throat) that would prevent full participation in the study.
• Electrocardiogram (ECG) readings outside the normal range and considered to be clinically significant by the Investigator.
• Subjects with:
• moderately severe or severe depression, as defined by a Patient Health Questionnaire (PHQ-9) total score of ≥10, or
• suicidal ideation, as defined by a PHQ-9 score ≥1 in response to question 9, "Thoughts that you would be better off dead, or of hurting yourself."
• Subjects with a history of psychosis, bipolar disorder, suicide attempt, schizophrenia, or any other significant psychiatric history that the Investigator believes may interfere with the subject's participation in the study.
• Subjects who have used an antipsychotic medication within the past 30 days. Subjects may be enrolled into the study if currently on a stable dose of antidepressant for the past 30 days and the dose is not expected to change throughout the duration of the study.
• Subjects who require any medications that may interfere with the absorption, metabolism, or excretion of the study drug.

Sponsors & Collaborators

• Chrono Therapeutics, Inc.: lead

Study Sites (5)

Coastal Clinical Research, Inc.

Mobile, Alabama, 36608, United States

Location

Clinical Research Consortium

Tempe, Arizona, 85283, United States

Location

Central Kentucky Research Associates, LLC

Lexington, Kentucky, 40509, United States

Location

Center for Pharmaceutical Research, LLC

Kansas City, Missouri, 64114, United States

Location

Rochester Clinical Research, Inc.

Rochester, New York, 14609, United States

Location

MeSH Terms

Conditions

Smoking Cessation; Tobacco Use Cessation

Interventions

Tobacco Use Cessation Devices

Condition Hierarchy (Ancestors)

Health Behavior; Behavior

Intervention Hierarchy (Ancestors)

Therapeutics

Study Officials

• Allen Wyler, MD

  Chrono Therapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: combination product

Study Record Dates

• First Submitted: April 21, 2017
• First Posted: June 6, 2017
• Study Start: August 7, 2017
• Primary Completion: October 18, 2017
• Study Completion: October 31, 2017
• Last Updated: December 4, 2017

Record last verified: 2017-11

Locations

US (5)